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Abstract: To evaluate clinical values of clinicopathologic and
18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/
computed tomography (PET/CT)-related parameters for prediction of
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)
mutation in colorectal cancer (CRC) and to investigate their variability
depending on C-reactive protein (CRP) levels.
In total, 179 CRC patients who underwent PET/CT scans before
curative resection and KRAS mutation evaluation following surgery
were enrolled. Maximum standardized uptake value (SUVmax), peak
standardized uptake value (SUVpeak), metabolic tumor volume, and
total lesion glycolysis were determined semiquantitatively. Associ-
ations between clinicopathologic and PET/CT-related parameters and
KRAS expression were analyzed.
Elevated CRP (>6.0mg/L; n¼ 47) was associated with higher
primary tumor size, higher SUVmax, SUVpeak, metabolic tumor
volume, and total lesion glycolysis, compared with those for the group
with a CRP lower than that the cutoff value (<6.0mg/L; n¼ 132).
Interestingly, the CRC patients (having CRP< 6.0mg/L) with KRAS
mutations had significantly higher (P< 0.05) SUVmax and SUVpeak
values than the patients expressing wild-type KRAS mutations. Multi-
variate analysis revealed SUVmax and SUVpeak to be significantly
associated with KRAS mutations (odds ratio¼ 3.3, P¼ 0.005, and
odds ratio¼ 3.9, P¼ 0.004), together with histologic grade and lymph
node metastasis.
18F-FDG uptake was significantly higher in CRC patients with
KRAS mutations and with normal CRP levels. A severe local inflam-, PhD, Young Hoon D, and
n, MD, PhD
genomic analysis to determine KRAS expression in CRC; however,
care should be exercised to guarantee proper patient selection.
(Medicine 95(1):e2236)
Abbreviations: 18F-FDG = 18F-fluorodeoxyglucose, BMI = body
mass index, CEA = carcinoembryonic antigen, CI = confidence
interval, CRC = colorectal cancer, CRP = C-reactive protein, EGFR
= epidermal growth factor receptor, GLUT1 = glucose transporter-
1, HNPCC = hereditary nonpolyposis colorectal cancer, KRAS = v-
Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, LNlymph
node, LVI = lymphovascular invasion, MTV = metabolic tumor
volume, OR = odds ratio, PET/CT = positron emission
tomography/computed tomography, ROC = receiver operating
characteristic, SUVmax = maximum standardized uptake value,
SUVpeak = peak standardized uptake value, TAM = tumor-
associated macrophage, TLG = total lesion glycolysis, VEGF =
vascular endothelial growth factor, VOI = volume of interest.
INTRODUCTION
C olorectal cancer (CRC) is the third most common cancer inthe world. After curative resection, adjuvant cytotoxic
chemotherapy and/or radiotherapy is recommended to improve
survival, especially in patients with stage II and III cancer.
Although CRC patients presenting with metastatic disease have
poor prognosis; nevertheless, some survival benefits are indi-
cated with newer targeted therapies: these therapies include
monoclonal antibodies against epidermal growth factor receptor
(EGFR) or vascular endothelial growth factor receptors. An
augmentation of cetuximab, an EGFR inhibitor, in first line
treatment has been reported to reduce the risk of progression in
patients with unresectable metastatic CRC disease with v-Ki-
ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-
type tumors.1 Notwithstanding, an accurate identification of
patients likely to respond to such targeted therapies may prevent
nonresponders from undergoing unwanted drug toxicity and
treatment cost.2 V-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog mutational status as evaluated by histologic tumor
examination is detected in approximately 30% to 40% of CRC
patients.3
18F-fluorodeoxyglucose (18F-FDG) positron emission
tomography/computed tomography (PET/CT) is widely used
in various malignancies for diagnosis, treatment response
assessment, surveillance, and prognostication.4 Although pre-portant for making critical decisions for
ly a few studies have described relation-
indings and KRAS mutation in CRC
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clinical studies demonstrated that higher 18F-FDGuptake inCRC
is associated with KRAS mutation,5,6 and a recent study by
Iwamoto et al7 suggested that upregulation of glucose transpor-
ter-1 (GLUT1) is a possible mechanism of higher 18F-FDG
accumulation in CRCwithKRASmutation.Meanwhile, Krikelis
et al8 reported that there is a lack of any association between
KRAS mutation and 18F-FDG-PET scan findings. Although
sample size and ethnic differences might be sources of bias,
the reasons for this discordance are not clearly understood.
Interestingly, Kawada et al6 excluded CRC patients who
had severe inflammation with C-reactive protein (CRP) levels
>5.0mg/L. CRP is an annular, metameric protein found in the
blood plasma. CRP levels rise in response to inflammation,
because CRP is an acute-phase protein of hepatic origin that
increases following interleukin-6 secretion from macrophages
and T cells. Local inflammation of cancer cells could impact
FDG uptake,9,10 and elevation in CRP may cause false-positive
results on 18F-FDG PET examinations.11 Although the actual
impact of CRP levels on 18F-FDG uptake in tumors is still
unclear, we assumed that abnormal CRP levels might imply the
presence of severe inflammation and act as a confounding factor
in the association between 18F-FDG uptake in CRC and
KRAS mutation.
In this study, we investigated clinicopathologic variables
and PET/CT-related parameters that could potentially predict
KRAS mutation in a large population of CRC patients and
evaluated the variability of their predictive values according to
CRP levels.
MATERIALS AND METHODS
Eligibility
The InstitutionalReviewBoard of our institute approved this
retrospective study, and the need for written informed consent
was waived. Patient records/information was anonymized and
deidentified before analysis. Using our prospectively collected
CRC database, we selected patients who underwent both 18F-
FDG PET/CT scan, before surgery, and KRAS mutation exam-
ination, between August 2006 and April 2014. Patients were
excluded from the selection if they were diagnosed with heredi-
tary nonpolyposis CRC or synchronous cancer, had undergone
preoperative chemotherapyor radiotherapy, andhadnoCRP level
results before the PET/CT scan was undertaken. Clinicopatho-
logic information on sex; age; body mass index; history of
diabetes mellitus; histologic grade; lymphovascular invasion;
carcinoembryonic antigen; tumor size; location of the primary
tumor in the proximal colon (cecal, ascending, and transverse
colon), distal colon (descending, sigmoid, and rectosigmoid
colon), or rectum; and pathologic T and N stages were extracted
from our database. Among the 221 patients who underwent 18F-
FDG PET/CT scan and KRASmutation analysis for CRC during
the study period, 179 with full clinicopathologic information
were included in this study (Fig. 1).
18F-FDS Positron Emission Tomography/
Computed Tomography Protocol
All patients fasted for atleast 6 hours and had blood glucose
levels less than 140mg/dL before intravenous administration of
18F-FDG (5.5MBq/kg of body weight). At 60 minutes after
Lee et alintravenous administration of 18F-FDG, PET/CT scans were
performedwith a hybrid PET/CTscanner (Biograph40TruePoint
or Biograph mCT 64, Siemens Healthcare Solutions USA, Inc.,
2 | www.md-journal.comKnoxville, TN). Whole-body CT images were obtained first for
attenuation correction using automatic dose modulation with a
reference of 40mA and 120 kV without contrast enhancement.
Then PET data were acquired from the skull base to the proximal
thigh for 3minutes per bed position in a three-dimensional mode.
Positron emission tomography images were reconstructed with
the ordered subset expectation maximization algorithm.
Image Analysis
18F-FDG PET/CT images were reviewed in consensus
from 2 experienced nuclear medicine physicians who were
blinded to clinicopathologic results at the time of the review.
The maximum standardized uptake value (SUVmax) was calcu-
lated as follows: SUVmax¼CmaxTBW/IA [Cmax: activity
concentration in the voxel of highest tumor activity (Bq/mL),
TBW: total body weight (kg), IA: injected activity (kBq)]. The
peak SUV (SUVpeak) was calculated as the average SUV within
a 1.2-cm diameter spherical volume of interest (VOI) positioned
around the voxel of the highest SUV.
The metabolic tumor volume (MTV) was measured using a
SUV-based automated contouring program (Syngo.via, version
VA20A, Siemens Medical Solutions, Erlangen, Germany).
First, a VOI was drawn large enough to incorporate the primary
tumor lesion in the axial, coronal, and sagittal 18F-FDG PET/CT
images. For the determination of metabolic volumes, we used
50% of SUVmax as a threshold, as 50% SUVmax threshold was
shown to best fit the actual volume of simulating phantom
lesions in previous studies.12 The software automatically pro-
duced the contour around the target lesion inside the VOI and
the voxels presenting SUV intensity higher than the threshold
within the contouring margin were incorporated to define the
tumor volume. Total lesion glycolysis (TLG) was calculated by
multiplying the tumor volume by the mean SUVof the volume.
V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene
Homolog Mutation Status Evaluation
FIGURE 1. Exclusion criteria and patient selection diagram.Deoxyribonucleic acid was extracted from formalin-fixed,
paraffin-embedded tumor tissue slides with the MagNA Pure 96
System (Roche Applied Science, Indianapolis, IN). V-Ki-ras2
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
Kirsten rat sarcoma viral oncogene homolog exon 2 was ampli-
fied by polymerase chain reaction using GeneAMP PCR system
veriti (Applied Biosystems, Foster City, CA), and was analyzed
using direct sequencing with the Applied Biosystems 3730XL
automated DNA analyzer (Applied Biosystems, Foster City, CA)
according to themanufacturer’s instruction. The sequences of the
primer were as follows: forward, GGAATTTTCATGATT-
GAATTTTGT; reverse, GAACATCATGGACCCTGACA.
Statistical Analysis
Our study group was divided into 2 subgroups (the normal
CRP group and the elevated CRP group) according to levels of
CRP before the PET/CT scan. All enrolled patients had CRP
data obtained within 2 days of the PET/CT scan. The differences
in clinicopathologic features and PET/CT parameters between
the KRAS wild-type group and the KRAS mutated group were
analyzed using 2-sided Pearson x2 test or Fisher exact test for
categorical variables and with a Student t test for continuous
variables. Then, the cutoff values of the variables providing the
best separation between the KRAS wild-type and mutated
groups were obtained using receiver operating characteristic
curve analyses, and used to dichotomize the data. Predictive
values of PET/CT parameters for the KRAS status were eval-
uated using multivariate logistic regression analysis along with
the clinicopathologic variables. Multicollinearity among PET/
CT-related parameters was evaluated by calculating Spearman
rank correlation coefficient before multivariate analysis. To
evaluate the impact of CRP status on predictive values of
PET/CT-related parameters for KRAS mutation, the same
statistical analyses were performed after the patients were
divided into the 2 groups: the normal CRP group and the
elevated CRP group. A P value <0.05 was considered to
indicate statistical significance. All calculations and analysis
were performed using the SPSS software package Version 20.0
(IBM Corp., Armonk, NY).
RESULTS
Patient Demographics
The characteristics of the 179 enrolled patients are shown in
Table 1. We evaluated the differences in clinicopathologic
variables and PET/CT-related parameters according to CRP
levels with a cutoff level of 6.0mg/L. The patients with elevated
CRP levels (n¼ 47; 26.2%) had primary tumors of larger size and
higher SUVmax, SUVpeak, MTV, and TLG, compared with those
with normal CRP levels (n¼ 132; 73.8%; P< 0.05, all). V-Ki-
ras2 Kirsten rat sarcoma viral oncogene homologmutations were
found in 60 patients (33.5%); 45 of these patients (75%) had
normal CRP levels, whereas the other 15 patients (25%) showed
elevated CRP levels. On review of medical records, none of the
patients with abnormal CRP levels had any severe systemic
inflammation or infection that might have contributed to
elevations in CRP level. The other clinicopathologic factors
did not show significant group differences.
Factors Associated With V-Ki-Ras2 Kirsten Rat
Sarcoma Viral Oncogene Homolog Mutation
Status
A cutoff level was determined by receiver operating
characteristic curve analysis for SUV , SUV , MTV,
Medicine  Volume 95, Number 1, January 2016max peak
and TLG, and the best discriminative values between those
tumors with wild-type and mutated KRAS were 10 (g/mL), 7.4
(g/mL), 10mL, and 50 g, respectively. Among the 179 patients
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.in total, the KRAS mutation group was found to have tumors
with lower histologic grade and more positive lymph node (LN)
metastasis, compared with the KRAS wild-type group
(P< 0.05, all; Table 2). None of the PET/CT-related parameters
showed significant differences between the 2 groups. Multi-
variate analysis revealed that histologic grade and LN metas-
tasis were independent predictors of KRAS mutation in CRC
patients [histologic grade: odds ratio (OR), 5.6; 95% confidence
interval (CI), 1.6–18.9; P¼ 0.006, and LN metastasis: OR, 3.4;
95% CI, 1.6–7.1; P¼ 0.001].
Subgroup Analysis According to C-Reactive
Protein Level
In the normal CRP group (CRP< 6; n¼ 132), the KRAS
mutation group showed higher SUVmax, SUVpeak, and lower
histologic grade than the KRAS wild-type group. In the pre-
diction of KRAS mutation, the sensitivity, specificity, and
accuracy were 60.0%, 50.3%, and 54.0% for SUVmax and
73.3%, 60.5%, and 67.8% for SUVpeak, respectively. Because a
strong positive correlation was found between SUVmax and
SUVpeak (Spearman rho¼ 0.955, P< 0.01), their predictive
values were analyzed in 2 separate multivariate models. In multi-
variate logistic regression analysis, higher SUVmax proved to be
significantly associated with KRASmutation together with lower
histologic grade and positive LN metastasis (SUVmax: OR, 3.3;
95% CI, 1.4–7.4; P¼ 0.005, histologic grade: OR, 6.0; 95% CI,
1.5–24.6; P¼ 0.013, positive LN metastasis: OR, 3.2; 95% CI,
1.3–7.8;P¼ 0.011;Table 3). In themodelwith SUVpeak, SUVpeak
was also found to be an independent predictor of KRASmutation,
alongwith histologic grade and LNmetastasis (SUVpeak: OR, 3.8;
95% CI, 1.5–9.3; P¼ 0.004, histologic grade: OR, 5.5; 95% CI,
1.3–22.8; P¼ 0.019, positive LN metastasis: OR, 3.1; 95% CI,
1.9–7.5; P¼ 0.015). In contrast, both lower 18F-FDG uptake and
positive LN metastasis were significantly associated with
KRAS mutation in the elevated CRP group (CRP 6; n¼ 47;
P< 0.05, all).
DISCUSSION
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
mutational analysis is essential before the initiation of anti-
EGFR therapy, because the antitumor efficacy of the drug is
dependent on KRAS mutation status. The most common
methods of assessing KRAS mutational status are through
molecular examination using biopsy or resected tissue. There,
however, there are several obstacles to this approach. First, in
case of metastatic sites, it is not always easy to access or obtain
adequate tissue samples for genetic testing. Second, because of
the nonhomogeneous, scattered distribution of tumor tissue,
there could be discordant results for KRAS mutation between
the biopsy tissue and the resected tumor.13,14 For these reasons,
Miles et al15 insisted that identification of an imaging signature
for the KRAS mutation would enable imaging to provide an
adjunct to histologic assessment, and demonstrated that
decision trees using imaging biomarkers could enhance the
predictive accuracy of KRAS mutation in CRC.
18F-FDG PET/CT is now being widely used in staging,
detecting recurrence, monitoring treatment response, and pre-
dicting prognosis in CRC; however, 18F-FDG PET/CT has been
used relatively rarely in the investigation of gene expression.
Only a few studies have evaluated the association between 18F-
FDG PET/CT and KRAS in Colorectal CancerFDG uptake and KRAS mutation. Kawada et al6 reported that
the SUVmax and the tumor-to-liver ratio were significantly
higher in the group of patients with KRAS mutation. Another
www.md-journal.com | 3
TABLE 1. Patient Characteristics According to C-Reactive Protein Status (n¼179)
Variables Total (n¼ 179) CRP< 6 (n¼ 132) CRP 6 (n¼ 47) P
Sex 0.603
Male:female 101:78 76:56 25:22
Age (years) 0.850
MeanSD 64.0 1.2 63.9 12.0 64.3 13.0
BMI (kg/m2) 0.583
MeanSD 23.1 3.2 23.2 3.1 22.9 3.5
DM 0.858
Yes 32 24 8
No 147 108 39
CEA (ng/mL) 0.202
MeanSD 10.4 31.2 7.6 16.3 18.2 54.6
Tumor location 0.080
Proximal colon 60 38 22
Distal colon 63 80 13
Rectum 56 44 12
Tumor size (cm) <0.001
MeanSD 5.1 3.4 4.5 2.4 6.2 2.6
Histologic grade

0.362
G1 14 12 2
G2, G3, etc. 165 120 45
LVI 0.666
Positive 49 35 14
Negative 130 97 33
pT 0.191
Tis, T1, and T2 30 25 5
T3 and T4 149 107 42
LN metastasis 0.630
Positive 93 70 23
Negative 86 62 24
Stage 0.891
0 and I 24 19 5
II 58 41 17
III 79 59 20
IV 18 13 5
SUVmax 0.029
MeanSD 12.0 6.3 11.4 6.2 13.7 6.2
SUVpeak 0.025
MeanSD 9.8 5.2 9.2 5.0 11.2 5.3
MTV 0.002
MeanSD 20.2 22.3 15.7 12.7 32.8 35.2
TLG <0.001
MeanSD 145.4 169.4 105.1 98.5 258.3 256.3
BMI¼ body mass index, CEA¼ carcinoembryonic antigen, CRP¼C-reactive protein, DM¼ diabetes mellitus, LN¼ lymph node,
LVI¼ lymphovascular invasion, MTV¼metabolic tumor volume, SD¼ standard deviation, SUVmax¼maximum standardized uptake value,
SUVpeak¼ peak standardized uptake value, TLG¼ total lesion glycolysis.
ll di
Lee et al Medicine  Volume 95, Number 1, January 2016retrospective study also showed that SUVmax was an indepen-
dent predictor of KRAS mutation in CRC, together with the
PET-based maximal tumor width.5 The accuracy of SUVmax
improved when combined with other imaging features:
SUVmax, CT texture, and perfusion.
15 Recently, Iwamoto
et al7 suggested that mutated KRAS causes higher 18F-FDG
accumulation, possibly by upregulation of GLUT1, through an
Union for International Cancer Control (UICC) classification: G1 we
mucinous and signet ring cell.in vitro study. In contrast, a recent clinical study reported a lack
of association between KRAS mutation and 18F-FDG uptake in
metastatic colon cancer.8 This study also showed that there was
4 | www.md-journal.comno significant association between GLUT1 mRNA expression
and KRAS mutation status.
Based on our results, we suppose that the lack of associ-
ation between KRAS mutation and 18F-FDG uptake, however,
might be because of improper patient selection. In the other
clinical studies, patients with high serum glucose levels, small-
sized tumors, or high CPR levels of >5mg/L were excluded on
fferentiated, G2 moderately differentiated, G3 poorly differentiated, etc.the rationale that those variables might interfere with 18F-FDG
uptake and accurate measurement of SUV.5,6 In the current
study, 18F-FDG uptake represented as SUVmax and SUVpeak had
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Univariate Analysis of Factors AssociatedWith V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Status According
to C-Reactive Protein Level
Total CRP< 6 CRP 6
Variables
Wild-Type KRAS
(n¼ 119)
Mutated KRAS
(n¼ 60)
Wild-Type KRAS
(n¼ 87)
Mutated KRAS
(n¼ 45) P
Wild-type KRAS
(n¼ 32)
Mutated KRAS
(n¼ 15) p
Sex 0.218 0.280 0.539
Male 71 30 53 23 18 7
Female 48 30 34 22 14 8
Age (years) 0.550 0.516 0.944
<60 41 18 30 13 11 5
60 78 42 57 32 21 10
BMI (kg/m2) 0.955 0.596 0.327
<25 87 44 64 35 23 9
25 31 16 23 10 8 6
DM history 0.260 0.596 0.327
Yes 24 8 17 7 7 1
No 95 52 70 38 25 14
CEA (ng/mL) 0.614 0.065 0.377
<5 76 36 58 29 18 7
5 43 24 29 16 14 8
Tumor location 0.583 0.420 0.348
Proximal 38 22 25 13 13 9
Distal 45 18 36 14 9 4
Rectum 36 20 26 18 10 2
Tumor size (cm) 0.875 0.689 0.552
<5 60 31 51 28 9 3
5 59 29 36 17 23 12
Histologic grade

0.011 0.013 0.575
G1 5 9 4 8 1 1
G2, G3, etc. 114 51 83 37 31 14
LVI 0.389 0.223 0.716
Positive 35 14 26 9 9 5
Negative 48 46 61 36 23 10
pT 0.981 0.489 0.105
Tis, T1, T2 20 10 15 10 5 0
T3, T4 99 50 72 35 27 15
LN metastasis 0.013 0.128 0.022
Positive 54 39 42 28 12 11
Negative 65 21 45 17 20 4
Stage 0.193 0.547 0.017
0 and I 18 6 13 6 5 0
II 43 15 30 11 13 4
III 46 33 37 22 9 11
IV 12 6 7 6 5 0
Maximum Standardized Uptake Value
MeanSD 11.8 5.7 12.6 7.4 0.423 10.4 4.6 13.2 8.1 0.037 15.3 6.5 10.4 4.1 0.012
10 63 38 0.186 39 32 0.004 24 6 0.020
<10 56 22 48 13 8 9
Peak Standardized Uptake Value
MeanSD 9.7 4.8 10.0 5.9 0.619 8.5 3.9 10.6 6.5 0.022 12.6 5.6 8.2 2.9 0.001
7.4 72 45 0.054 48 37 0.002 24 8 0.137
<7.4 47 15 39 8 8 7
Metabolic Tumor Volume (mL)
MeanSD 21.1 25.9 18.5 12.5 0.452 16.2 14.5 14.8 8.1 0.556 34.4 41.2 29.3 16.7 0.647
13 60 38 0.101 38 25 0.195 22 13 0.189
<13 59 22 49 20 10 2
Total Lesion Glycolysis (g)
MeanSD 153.7 196.9 128.9 93.0 0.255 101.6 106.8 112.0 80.8 0.568 295.2 295.8 179.6 110.7 0.059
50 86 49 0.168 58 36 0.109 28 13 0.936
<50 33 11 29 9 4 2
rote
iatio
d, G2
Medicine  Volume 95, Number 1, January 2016 FDG PET/CT and KRAS in Colorectal Cancera positive correlation with KRAS mutation only in the normal
CRP group; meanwhile, it showed an inverse correlation in
BMI¼ body mass index, CEA¼ carcinoembryonic antigen, CRP¼C-reactive p
homolog, LN¼ lymph node, LVI¼ lymphovascular invasion, SD¼ standard dev
Union for International Cancer Control (UICC) classification: G1well differentiatethe elevated CRP group and lost its predictive power in the
whole population. 18F-FDG is a glucose analogue and thus a
metabolic tracer, not a cancer-specific tracer. Secondary local
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.inflammation following treatment has been shown to induce
false-positive 18F-FDG accumulation, thus hampering the acute
in, DM¼ diabetes mellitus, KRAS¼ v-Ki-ras2 Kirsten rat sarcoma viral oncogene
n.
moderately differentiated,G3 poorly differentiated, etc.mucinous and signet ring cell.assessment of treatment response. Kubota et al10 demonstrated
that newly formed granulation tissue around tumors and macro-
phages showed greater FDG uptake than did viable tumor cells,
www.md-journal.com | 5
TABLE 3. Multivariate Analysis and Estimation of Odds Ratios for Predicting V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene
Homolog Mutation in Patients With Normal C-Reactive Protein Level (n¼132)
Model With SUVmax Model With SUVpeak
OR (95% CI) P OR (95% CI) P
Histologic grade

G1 versus G2/G3/etc. 6.0 (1.5–24.6) 0.013 5.5 (1.3–22.8) 0.019
LVI Positive 0.5 (0.2–1.2) 0.125 0.5 (0.2–1.2) 0.125
LN metastasis Positive 3.2 (1.3–7.8) 0.011 3.1 (1.3–7.5) 0.014
SUVmax 10 versus <10 3.3 (1.4–7.4) 0.005
SUVpeak 7.4 versus <7.4 3.8 (1.5–9.3) 0.004
CI¼ confidence interval, LN¼ lymph node, LVI¼ lymphovascular invasion, OR¼ odds ratio, SUVmax¼maximum standardized uptake value,
ll di
Lee et al Medicine  Volume 95, Number 1, January 2016and a maximum of 29% of the 18F-FDG uptake was derived from
nontumor tissues, such as macrophages and granulation tissues,
which was indicative of confusing 18F-FDG uptake in the
inflammatory response to tumor cells. Diederichs et al11 eval-
uated the accuracy of FDG-PET concerning the differentiation of
benign and malignant pancreatic masses according to CRP level.
In the differentiation of benign and malignant lesions, specificity
was significantly lower for patients with elevated CRP levels than
for patients with unknown or normal CRP levels (40% versus
87%, P< 0.01). They concluded that elevated CRP may cause
false-positive results in FDG-PET examinations. Nevertheless, to
the best of our knowledge, the relationships among CRP level,
local inflammation, and tumoral 18F-FDG uptake in CRC have
not been investigated thoroughly.
Causes of local inflammation in CRC can be postulated in
2 aspects: 1 is from host-to-tumor response and the other from
gross peritumoral tissue damage. Solid tumors comprise malig-
nant cells, resident stromal cells, and infiltrating inflammatory
leucocytes.16 Peritumoral inflammatory lesions are extensively
infiltrated by activated macrophages, so-called tumor-associ-
ated macrophages.17,18 Besides the host response, CRC may be
accompanied by tumor necrosis, perforation, abscess formation,
or bowel ischemia that predisposes it to inflammatory cell
infiltration. A high-degree local inflammatory cell response
is reportedly more commonly present in rectal tumors,19
whereas an elevated systemic inflammatory response is more
commonly present in colonic tumors.20 Those phagocytes are
also effective accumulators of 18F-FDG because of their con-
stitutively high endocytic activity,10 and thus, accumulation of
inflammatory cells is often associated with false-positive results
in 18F-FDG-based studies.21–23 Admittedly, CRP is an acute-
phase marker for systemic inflammation and therefore may be
not directly related to local inflammatory response. A high-
grade local inflammatory response, however, can switch to a
systemic inflammatory response as tumor growth continues or
inflammation is aggravated.24 For those reasons, abnormal
elevation of CRP may suggest the presence of local inflam-
mation in CRC, and accurate quantification of 18F-FDG uptake
in CRC could be hampered in this condition. The current study
reinforces the importance of proper patient selection that has
been highlighted in other studies.11
18F-FDGPET/CT has several advantages over other potential
biologic or imaging markers in prediction of KRASmutation. This
SUVpeak¼ peak standardized uptake value.
Union for International Cancer Control (UICC) classification: G1 we
mucinous and signet ring cell.technique is a noninvasive functional imaging modality that pro-
vides quantitative information on the glucose uptake of tumors as
well as qualitative features of tumors that may provide guidance on
6 | www.md-journal.comdecisions regarding biopsy sites. In addition, the metabolic
parameters of the primary lesion can be obtained before or without
surgery. Moreover, contouring of the tumor and measurement of
SUVmax are less operator dependent and there is less interobserver
variability, compared with conventional imaging modalities.25–27
Nevertheless, for prediction ofKRASmutation in CRC, the overall
accuracy of SUVmax alone has only been found to be modest,
ranging from 60% to 75%, and this was similar in our study.
Although the accuracy could be improved when combined with
other clinicopathologic or imaging parameters, 18F-FDG PET/CT
cannot replace conventional methods to confirm KRAS mutation,
and it should rather be used as a complementary tool when
histopathologic results are equivocal.
There are several limitations in this study.First,CRP is related
to local inflammation, although probably indirectly. Therefore,
peritumoral inflammation does affect the measurement of SUV in
primary tumors; however, this study lacks histopathologic confir-
mation of secondary local inflammation and it is unclear how
accurately CRP level reflects the severity of such local inflam-
mation. Second, we used 0 to 6mg/L as the normal range of CRP
levels. These values, however, may be less generalizable because
reference CRP values vary from laboratory to laboratory, as does
the definition of severe inflammation in terms of CRP. Lastly,
despite a larger populationofCRCpatients, thiswas a retrospective
study conducted at a single tertiary referral center.
In conclusion, 18F-FDG uptake in primary CRCs with
mutated KRAS was significantly higher than in CRCs with
wild-type KRAS, and SUVmax and SUVpeak were independent
predictors of KRAS mutation together with positive LN metas-
tasis. This relationship, however, changed in patients with
elevated CRP levels, and we suppose that severe local inflam-
mation might have affected the measurement of tumoral 18F-
FDG uptake. The current study reinforced the predictive value
of 18F-FDG uptake for KRAS mutation in addition to stressing
the importance of proper patient selection in a correlative study.
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